The risks of the first pill for postpartum depression
Zurzuvae, the first ever pill to treat postpartum depression is here. It’s faster, less invasive and has milder side effects than brexanolone, the only other FDA-approved treatment before it. How exactly does it work? And does it have side effects or risks? Sanjana Bhambhani interviewed the Chief of Columbia University's Division of Women’s Mental Health, Dr. Catherine Monk, to explore the concerns around this new drug.
Video by Sanjana Bhambhani, Ingrid Holmquist and Anna Bressanin